Fine-tuning anti-tumor immunotherapies via stochastic simulations

BMC Bioinformatics

Volumn 13, Issue SUPPL.4, 2012, Pages

  Caravagna, Giulio ^a   Barbuti, Roberto ^b   D'Onofrio, Alberto ^c  

^a CNR   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMORS; CONTINUOUS VARIABLES; CONTINUOUS-TIME; DELIVERY SCHEDULES; DETERMINISTIC MODELS; HYBRID MODEL; PIECE-WISE CONSTANTS; RESIDUAL TUMORS; SIDE EFFECT; STOCHASTIC SIMULATIONS; SYNERGISTIC EFFECT; TUMOR CELLS;

CHEMOTHERAPY; IMMUNE SYSTEM; RANDOM PROCESSES; STOCHASTIC MODELS;

TUMORS;

INTERLEUKIN DERIVATIVE;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; COMPUTER SIMULATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; STATISTICS;

COMPUTER SIMULATION; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKINS; NEOPLASMS; STOCHASTIC PROCESSES;

EID: 84864913665     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-13-S4-S8     Document Type: Article

References (64)

1. d'Onofrio A, Gandolfi A, Rocca A. The dynamics of tumor-vasculature interaction suggests low-dose, time-dense antiangiogenic schedulings. Cell Prolif 2009, 42:317-329. 10.1111/j.1365-2184.2009.00595.x, 19438898.
2. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003, 21:807-839. 10.1146/annurev.immunol.21.120601.141135, 12615893.
3. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909, 5:273-290.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
5. d'Onofrio A. Tumor evasion from immune system control: strategies of a MISS to become a MASS. Chaos Solitons and Fractals 2007, 31:261-268.
6. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002, 12:43-50. 10.1006/scbi.2001.0402, 11926411.
7. Vicari AP, Caux C, Trinchieri G. Tumor escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002, 12:33-42. 10.1006/scbi.2001.0400, 11926410.
8. d'Onofrio A, Ciancio A. Simple biophysical model of tumor evasion from immune system control. Phys Rev E Stat Nonlin Soft Matter Phys 2011, 84:031910.
9. De Vito VT, Hellman J, Rosenberg SA. Cancer: Principles and Practice of Oncology 2005, Philadelphia: JP Lippincott, 9th North American Edition.
10. Agarwala SS. New applications of cancer immunotherapy. Semin Oncol 2002, 29(3 Suppl 7):1-4.
11. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003, 44:65-75,. 10.1016/S0302-2838(03)00191-X, 12814677.
12. Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B. Immunotherapy and prostate cancer. Cancer Treat Rev 2003, 29:199-209. 10.1016/S0305-7372(03)00005-7, 12787714.
13. De Pillis LG, Radunskaya AE, Wiseman CL. A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth. Cancer Res 2005, 65:7950-7958.
14. Kirschner D, Panetta JC. Modeling immunotherapy of the tumor - immune interaction. J Math Biol 1998, 37:235-252. 10.1007/s002850050127, 9785481.
15. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother 2008, 57:425-439. 10.1007/s00262-007-0387-z, 17823798.
16. Cappuccio A, Elishmereni M, Agur Z. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 2006, 66:7293-7300. 10.1158/0008-5472.CAN-06-0241, 16849579.
17. Meloni G, et al. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia 2002, 16:2016-2018. 10.1038/sj.leu.2402566, 12357352.
18. De Lisi C, Rescigno A. Immune surveillance and neoplasia: a minimal mathematical model. Bull Math Biol 1977, 39(2):201-221.
19. Stepanova NV. Course of the immune reaction during the development of a malignant tumor. Bioph 1980, 24:917-923.
20. Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS. Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis. Bull Math Biol 1994, 56:295-321.
21. Nani F, Freedman HI. A mathematical model of cancer treatment by immunotherapy. Math Biosci 2000, 163:159-199. 10.1016/S0025-5564(99)00058-9, 10701303.
22. Kuznetsov VA, Knott GD. Modeling tumor re-growth and immunotherapy. Math Comp Mod 2001, 33:1275-1287.
23. de Vladar HP, González JA. Dynamic response of cancer under the influence of immunological activity and therapy. J Theor Biol 2004, 227:335-348. 10.1016/j.jtbi.2003.11.012, 15019501.
24. d'Onofrio A. A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences. Phys D 2005, 208:220-235.
25. Kirschner D, Tsygvintsev A. On the global dynamics of a model for tumor immunotherapy. Math Biosci Eng 2009, 6(3):573-583.
26. d'Onofrio A. Tumor-immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy. Math Mod and Meth in App Sci 2006, 16:1375-1401.
27. d'Onofrio A, Gatti F, Cerrai P. Delay-induced oscillatory dynamics of tumor-immune system interaction. Math and Comp Mod 2010, 51:572-591.
28. d'Onofrio A. Bounded-noise-induced transitions in a tumor-immune system interplay. Phys Rev E Stat Nonlin Soft Matter Phys 2010, 81:021923.
29. Bellomo N, Delitala M. . From the mathematical kinetic, and stochastic game theory to modelling mutations, onset, progression and immune competition of cancer cells. Phys of Life Rev 2008, 5:183-206.
30. Bellomo N, Forni G. Complex multicellular systems and immune competition: New paradigms looking for a mathematical theory. Current Topics In Developmental Biology 2008, 81:485-502.
31. Pappalardo F, Lollini PL, Castiglione F, Motta S. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics 2005, 21(12):2891-2897. 10.1093/bioinformatics/bti426, 15817697.
32. Pennisi M, Pappalardo F, Palladini A, Nicoletti G, Nanni P, Lollini PL, Motta S. Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics 2010, 11(Suppl 7):S13. 10.1186/1471-2105-11-S7-S13, 3040527, 21210980.
33. Kennedy BJ. . Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. Blood 1970, 35:751-760.
34. Vodopick H, Rupp EM, Edwards CL, Goswitz FA, Beauchamp JJ. Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. N Engl J Med 1972, 286:284-290. 10.1056/NEJM197202102860603, 4500260.
35. Gatti R, et al. Cyclic Leukocytosis in Chronic Myelogenous Leukemia: New Perspectives on Pathogenesis and Therapy. Blood 1973, 41:771-783.
36. Mehta BC, Agarwal MB. Cyclic oscillations in leukocyte count in chronic myeloid leukemia. Acta Haematol 1980, 63:68-70. 10.1159/000207373, 6768216.
37. Sohrabi A, Sandoz J, Spratt JS, Polk HC. Recurrence of breast cancer: Obesity, tumor size, and axillary lymph node metastases. JAMA 1980, 244(3):264-265. 10.1001/jama.1980.03310030040023, 7382092.
38. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997, 79(12):2361-2370. 10.1002/(SICI)1097-0142(19970615)79:12<2361::AID-CNCR10>3.0.CO;2-P, 9191524.
39. Caravagna G, d'Onofrio A, Milazzo P, Barbuti R. Tumour suppression by immune system through stochastic oscillations. J Theor Biol 2010, 265(3):336-345. 10.1016/j.jtbi.2010.05.013, 20580640.
40. Guckenheimer J, Holmes PJ. Nonlinear Oscillations, Dynamical Systems and Bifurcation of Vector Fields. 1983, Springer, New York.
41. Hale JK, Kocak H. Dynamics and Bifurcation. 1991, Springer, New York.
42. Gillespie DT. A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions. J of Comp Phys 1916, 22(4):403-434.
43. Gillespie DT. Exact Stochastic Simulation of Coupled Chemical Reactions. J of Phys Chem 1977, 81:2340-2361.
44. Salis H, Kaznessis Y. Accurate hybrid stochastic simulation of a system of coupled chemical or biochemical reactions. J Chem Phys 2005, 122:054103.
45. Alfonsi A, Cances E, Turinici G, Di Ventura B, Huisinga W. Exact simulation of hybrid stochastic and deterministic models for biochemical systems. INRIA Tech Report 2004, 5435.
46. Lecca P. A time-dependent extension of Gillespie algorithm for biochemical stochastic π-calculus. Proceedings of the 2006 ACM symposium on Applied computing 23-27 April 2006 Dijon 2006, 137-144. Haddad:ACM, Hisham M.
47. Anderson DF. A modified next reaction method for simulating chemical systems with time dependent propensities and delays. J Chem Phys 2007, 127:214107. 10.1063/1.2799998, 18067349.
48. Kirschner D, Arciero JC, Jackson TL. A Mathematical Model of Tumor-Immune Evasion and siRNA Treatment. Discr and Cont Dyn Systems 2004, 4:39-58.
49. DeBoer RJ, Hogeweg P, Hub F, Dullens J, DeWeger RA, DenOtter W. Macrophage T Lymphocyte interactions in the anti-tumor immune response: A mathematical model. J Immunol 1985, 134:2748-2758.
50. d'Onofrio A. Stability property of Pulse Vaccination Strategy in SEIR epidemic model. Math Biosci 2002, 179(1):57-72. 10.1016/S0025-5564(02)00095-0, 12047921.
51. d'Onofrio A. Pulse Vaccination Strategy in SIR epidemic model: global stability, vaccine failures and double vaccinations. Math and Comp Model 2002, 36(4-5):461-478.
52. Shahrezaei V, Ollivier JF, Swain PS. Colored extrinsic fluctuations and stochastic gene expression. Mol Syst Biol 2008, 4:196. 2424296, 18463620.
53. Caravagna G. Formal Modeling and Simulation of Biological Systems With Delays. PhD thesis 2011, Università di Pisa, Dipartimento di Informatica.
54. Barrio M, Burrage K, Leier A, Tian T. Oscillatory regulation of Hes1: discrete stochastic delay modelling and simulation. PLoS Comput Biol 2006, 2(9):e117. 10.1371/journal.pcbi.0020117, 1560403, 16965175.
55. Bratsun D, Volfson D, Tsimring LS, Hasty J. Delay-induced Stochastic Oscillations in Gene Regulation. PNAS 2005, 102(41):14593-14598. 10.1073/pnas.0503858102, 1253555, 16199522.
56. Barbuti R, Caravagna G, Maggiolo-Schettini A, Mi-lazzo P. On the Interpretation of Delays in Delay Stochastic Simulation of Biological Systems. Proceedings of the 2nd Int Workshop on Computational Models for Cell Processes (CompMod'09) EPTCS 2009, 6:17-29. Back R, Petre I, de Vink EP.
57. Barbuti R, Caravagna G, Maggiolo-Schettini A, Milazzo P. Delay Stochastic Simulation of Biological Systems: A Purely Delayed Approach. Trans on Comp Sys Bio 2011, XIII 6575:61-84.
58. Levi F, Schibler U. Circadian Rhythms: Mechanisms and Therapeutic Implications. Annu Rev Pharmacol Toxicol 2007, 47:593-628. 10.1146/annurev.pharmtox.47.120505.105208, 17209800.
59. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436. 10.1038/nrc1369, 15170445.
60. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D'Alessandro C, Cinieri S, Preda L, Colleoni M. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006, 17:961-967. 10.1097/01.cad.0000224454.46824.fc, 16940806.
61. Gillespie DT. Approximated Accelerated Stochastic Simulation of Chemically Reacting Systems. J of Chem Phys 2001, 115(4):1716-1733.
62. Gillespie DT, Petzold LR. Numerical Simulation for Biochemical Kinetics. System modeling in cell biology: from concepts to nuts and bolts 2001, MIT Press.
63. d'Onofrio A, Gandolfi A. Resistance to antitumor chemotherapy due to bounded-noise-induced transitions. Phys Rev E Stat Nonlin Soft Matter Phys 2010, 82:061901.
64. Daalhuis ABO. Hypergeometric function. NIST Handbook of Mathematical Functions 2010, Cambridge University Press, Olver FWJ, et al., http://dlmf.nist.gov/15